Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

ARIAD reports lower Q4 net loss, provides guidance for 2015

ARIAD Pharmaceuticals, Inc., an oncology company, has reported that net loss for the fourth quarter ended December 31, 2014 was $5.75 million, or $0.03 loss per share, compared to a net loss of $74.16 million, or $0.40 loss per share, for the same quarter ended December 31, 2013. For 2015, the company expects net product revenues from sales of Iclusig to be in the range of $130 million to $140 million.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

NGM and Merck collaborate to develop and commercialize new biologic therapies

NGM Biopharmaceuticals, Inc. and Merck have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Rigel and Bristol-Myers collaborate to develop cancer immunotherapies

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's portfolio of small molecule TGF beta receptor kinase inhibitors.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Genmab enters into DuoBody technology agreement with BioNovion

Genmab A/S, a biotechnology company, has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

IPC Healthcare reports flat net income for Q4, provides guidance for 2015

IPC Healthcare, Inc., a provider of hospitalist services, has reported that net income for the fourth quarter ended December 31, 2014 was $9.53 million, or $0.54 per diluted share, compared to $9.53 million, or $0.54 per diluted share, for the same quarter ended December 31, 2013. For 2015, the company expects adjusted earnings per diluted share to be in the range of $2.14 to $2.27.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

LifeMap Sciences launches gene set analysis tool

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., has launched GeneAnalytics v1.1, a gene set analysis tool that contextualizes RNAseq and microarray-derived gene expression patterns and function signatures.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Meda receives FDA approval for nasal spray to treat allergic rhinitis

Meda AB, a specialty pharmaceutical company, has received approval from the FDA for Dymista, a single formulation azelastine hydrochloride and fluticasone propionate nasal spray to relieve the symptoms of seasonal allergic rhinitis in patients 6-11 years of age who require treatment with both components.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Genetic Technologies appoints CEO

Genetic Technologies Limited, a molecular diagnostics company, has appointed Eutillio Buccilli as CEO of the company following the resignation of Alison Mew.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Celldex receives breakthrough therapy designation from FDA for GBM drug

Celldex Therapeutics, Inc., a biopharmaceutical company, has received breakthrough therapy designation from the FDA for rindopepimut, or Rintega, for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM.

Published By MarketLine
26 Feb 2015
NewsWire
NewsWire

Arup completes construction of new mental health hospital in Liverpool, UK

Arup Group Limited, a professional services firm, has completed construction of Clock View, a new GBP25 million mental health hospital, in Liverpool, UK.

Published By MarketLine
26 Feb 2015

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.